Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. (Q37831317)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

review article

1 reference

title

Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Mariano A Giorgi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Hernán Cohen Arazi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Guillermo Di Girolamo

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

language of work or name

English

0 references

publication date

22 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

1285-1295

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Nonresponders to clopidogrel: pharmacokinetics and interactions involved.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Pharmacology of emerging novel platelet inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Ca

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Propensity score adjustment with multilevel data: setting your sites on decreasing selection bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Risk of combining PPIs with thienopyridines: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Structure and stereochemistry of the active metabolite of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.550573

10.1517/14656566.2011.550573

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21254864%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference